Aurinia Pharmaceuticals Reports Q3 Earnings Beat with $83.7 Million in Revenue
Aurinia Pharmaceuticals (AUPH) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a GAAP earnings per share (EPS) of $0.23, surpassing estimates by $0.01, while total revenue reached $83.7 million, representing a 13.9% increase year-over-year. Despite the earnings beat and steady revenue growth driven by its product portfolio, the company's stock experienced a significant decline of approximately 10% in after-hours trading. Market analysts have noted that while key products like Lupkynis remain strong revenue drivers, long-term upside may be constrained by increasing competition and potential patent risks.
Tickers: $AUPH